close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

161.38 -2.56 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
 
Via Benzinga
First Trust's New Small-Cap ETF Aims To Combine Growth With Income
First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%. 
Via Benzinga
Topics ETFs
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025. 
Via Benzinga
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
 
Via Benzinga
Peering Into Insmed's Recent Short Interest
 
Via Benzinga
Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
 
Via Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
 
Via Benzinga
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert
Insmed specializes in treatments for rare and serious diseases and is currently advancing its lead asset, brensocatib, a potential first-in-class therapy for bronchiectasis. 
Via Stocktwits
Topics Government
How Is The Market Feeling About Insmed?
 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index looks at five stocks receiving increased attention from readers during the week and provides potential reason why. 
Via Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years
 
Via Benzinga
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
Via The Motley Fool
Topics Stocks
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
How Is The Market Feeling About Insmed?
 
Via Benzinga
Demystifying Insmed: Insights From 7 Analyst Reviews
 
Via Benzinga
Insmed's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the past week. Several of this week's stocks may have gotten a Trump bump. 
Via Benzinga
Topics Government
A Glimpse of Insmed's Earnings Potential
 
Via Benzinga
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today
 
Via Benzinga
Peering Into Insmed's Recent Short Interest
 
Via Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years
 
Via Benzinga
(INSM) - Analyzing Insmed's Short Interest
 
Via Benzinga
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today
 
Via Benzinga
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
NASDAQ:INSM Shows Potential for a Breakout.
INSMED INC (NASDAQ:INSM) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today